Sangamo's lead zinc-finger therapy flops in diabetic neuropathy.
Michael
M
Eisenstein
D017322:Clinical Trials, Phase II as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000191:economics*; D017277:Drug Approval; D006801:Humans; D007221:Industry / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000191:economics* / Q000627:therapeutic use; D016335:Zinc Fingers
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A